Dimerix Limited · ASX:DXB
Dimerix — E&P Healthcare Conference 2026
22 slides from Dimerix's conference presentation, Sep 16, 2026
Slide 1: Dimerix presents at E&P Healthcare Conference 2026
For Immediate Release DIMERIX PRESENTS AT For personal use only E&P HEALTHCARE CONFERENCE 2026 MELBOURNE, Australia, 16 September 2026: Dimerix Limited (ASX: DXB), a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to advise that CEO and Managing Director, Dr
Slide 2: About Dimerix
About Dimerix Dimerix Limited (ASX: DXB) is a clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases with significant unmet medical need. The Company’s lead program, DMX-200, is currently in Phase 3 clinical development for focal segmental glomerulosclerosis
Slide 3: Dimerix Forward Looking Statement
Dimerix Forward Looking Statement This release includes forward-looking statements that are subject to risks and uncertainties. Although management believes that the expectations reflected in the forward-looking statements are reasonable at this time, Dimerix can give no assurance that these expecta
Slide 4: E&P Healthcare Conference September 2026
rsonal use only E&P Healthcare Conference 16 September 2026 Developing new therapies to treat kidney Authorised for lodgement by the Board of the Company diseases with unmet clinical needs
Slide 5: Forward looking statements
Forward looking statements This presentation includes forward-looking statements that are subject to risks and uncertainties. Although we believe that the expectations reflected rsonal use only in the forward looking statements are reasonable at this time, Dimerix can give no assurance that these ex
Slide 6: DMX-200 in Focal Segmental Glomerulosclerosis (FSGS)
rsonal use only DMX-200 in: Focal Segmental Glomerulosclerosis (FSGS)
Slide 7: DMX-200: Phase 3 Global Opportunity
DMX-200: Phase 3 Global Opportunity rsonal use only 5 commercial up to $1.9 billion Phase 3 trial FSGS indication Reduced risk Orphan drug partners in total recruitment is a rare disease Proteinuria endpoint passed blinded designations DMX-200 licensed development and complete in that causes scarrin
Slide 8: Cycle of damage in glomerular diseases
Cycle of damage in glomerular diseases What is FSGS? Existing blood pressure medication rsonal use only Glomeruli exposed to stress from high blood pressure DMX-200 Focal = some 1 Segmental = sections High blood pressure causes hyperfiltration Glomerulo = of the kidney filtering units within filter
Slide 9: Measuring kidney damage – surrogate endpoints
Measuring kidney damage – surrogate endpoints 1. Proteinuria is the quantity of protein in the urine 2. Estimated glomerular filtration rate (eGFR) rsonal use only Treatments, such as DMX-200, aim to A healthy kidney is a good filter and allows little to no protein into bring the FSGS slope back up:
Slide 10: Phase 3 clinical trial design and timeline
European Renal Association Posters 2025 phase 3 clinical trial A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with FSGS receiving an ARB (n=≥286) rsonal use only Background Phase 3 Trial Timeline Open Label Extension Successful interim ana
Slide 11: Adult patient recruitment by territory
adult patient recruitment by territory rsonal use only Trial designed for potential approval globally Recruitment completed (adult population)1 333 Adult patients recruited, randomised and dosed (target ≥286)2 Latin America Asia Pacific US / Europe 1. ASX release 15 December 2025; 2. Final numbers o
Slide 12: Summary of licensing deals for DMX-200 to date
Summary of licensing deals for DMX-200 to date Dimerix has successfully partnered DMX-200 across multiple key markets rsonal use only Licensing deals collectively 1 2 3 4 5 valued up to ~AU$1.9 United States China,S.Korea.SEA EU, CA, AU, NZ Japan GCC, Iraq billion AU$48 million1 AU$14.1 AU$10.8 AU$7
Slide 13: DMX-200 - geographic diversification of fee revenue
DMX-200 - geographic diversification of fee revenue Collectively, five commercial agreements valued up to A$1.9 billion across upfront + milestone fees:1 rsonal use only On signing Short Term Potential Longer Term Potential Upfront fees Milestone Payments Milestone Payments Royalties Diversified rev
Slide 14: DMX-652 in Acute Kidney Injury (AKI)
rsonal use only DMX-652 in: Acute Kidney Injury (AKI)
Slide 15: DMX-652: Phase 2 in acute kidney injury
DMX-652: Phase 2 in acute kidney injury A complementary, clinical-stage pipeline addition rsonal use only Leverages existing expertise Large value potential Strategic value Large and growing market First and best in class • Secured a Phase 2 ready • First-in-class USP30 • Dimerix team are experts •
Slide 16: What is AKI associated with cardiac surgery
What is AKI associated with cardiac surgery Currently no approved disease-modifying therapies rsonal use only 1 Cardiac Surgery 2 Ischaemia 3 Reperfusion: restores blood flow to kidney Mitochondria rupture ~26% Healthy mitochondria of patients undergoing cardiac surgery suffer kidney injury kidney d
Slide 17: DMX-652 – a unique, novel mechanism
DMX-652 – a unique, novel mechanism DMX-652 aims to reactivate the body's natural quality-control system to remove damaged mitochondria (a process called mitophagy) before they trigger kidney cell death rsonal use only 1. Inhibit USP30 2. Promote mitophagy 3. Remove damaged mitochondria DMX-652 inhi
Slide 18: Proposed Phase 2 clinical trial design
Proposed phase 2 clinical trial design A multicentre, double-blind, randomised, placebo-controlled study evaluating the safety and efficacy of DMX-652 in patients at high risk of AKI following cardiac surgery (n=160) rsonal use only Screening/randomisation Treatment phase Follow up • Patients identi
Slide 19: DMX-200 and DMX-652: complementary growth pillars
DMX-200 and DMX-652: complementary growth pillars Strategic fit: shared renal capabilities, shared regulatory/clinical infrastructure, shared small-molecule know-how rsonal use only DMX-200 DMX-652 Focal Segmental Glomerulosclerosis Acute kidney injury associated with (FSGS) rare kidney disease 1 Sh
Slide 20: Key potential value inflection points
Key potential value inflection points Disciplined, stage-gated capital deployment focused on the clinical value inflection1 rsonal use only Paediatric recruitment completion; first patient completes open label Phase 3 ACTION3 NDA dossier submission extension study IDMC safety review Phase 3 FSGS rea
Slide 21: Corporate overview
Corporate overview S H A R E P R I C E Ticker Symbol ASX: DXB rsonal use only Cash Balance (Jun26)* $16.2 million Market Capitalisation1 $150 million Share price1 $0.25 Total ordinary shares on issue1 600,396,776 Average Daily Liquidity by value for $0.55 million past 90 trading days2 S UBSTA N T IA
Slide 22: ESG Statement and contact details
(ASX:DXB) rsonal use only A biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on kidney diseases. W E L L P O S I T I O N E D TO D E L I V E R AGA I N ST ST R AT EG I C P L A N ESG Statement Dimerix is committed to integrating Environm